| pubmed-article:15297200 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15297200 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:15297200 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15297200 | pubmed:dateCreated | 2004-8-6 | lld:pubmed |
| pubmed-article:15297200 | pubmed:abstractText | Incorporating topotecan into standard platinum/taxane chemotherapy for advanced ovarian cancer has been complicated by myelosuppression. This study evaluated sequential doublets of topotecan and carboplatin, followed by paclitaxel and carboplatin, in newly diagnosed advanced ovarian cancer patients. | lld:pubmed |
| pubmed-article:15297200 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15297200 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15297200 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15297200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15297200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15297200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15297200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15297200 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15297200 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15297200 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:AsmarLinaL | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:GordonAlan... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:YoungJames... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:MessingMark... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:StreetDaron... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:PippittCharle... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:BaileyCheryl... | lld:pubmed |
| pubmed-article:15297200 | pubmed:author | pubmed-author:SavageJohnJ | lld:pubmed |
| pubmed-article:15297200 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15297200 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:15297200 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15297200 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15297200 | pubmed:pagination | 533-9 | lld:pubmed |
| pubmed-article:15297200 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:meshHeading | pubmed-meshheading:15297200... | lld:pubmed |
| pubmed-article:15297200 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15297200 | pubmed:articleTitle | Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. | lld:pubmed |
| pubmed-article:15297200 | pubmed:affiliation | Texas Oncology, P.A., Charles A. Sammons Cancer Center, Dallas, TX 75246, USA. agordonmd@earthlink.net | lld:pubmed |
| pubmed-article:15297200 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15297200 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15297200 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15297200 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15297200 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
